The Vall d´Hebron Institute of Oncology (VHIO) Seeks a “Predoctoral Researcher”
Reference: Ref. 14-2023
Application deadline: 07.03.2023
Number of vacancies: 1
VHIO has been awarded as a Center of Excellence Severo Ochoa, granted within the subprogram of the Spanish Institutional Strengthening of the State Plan for Scientific and Technical Research & Innovation, recognizes national research centers that demonstrate scientific leadership of excellence and impact at global level. The aid has been funded by the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S / AEI / 10.13039 / 501100011033)
Job description:
The Cancer Cell Cycle Group led by Dr. Marcos Malumbres offers a position for a Predoctoral researcher in cancer cell proliferation.
The candidate will be involved in the characterization of the molecular events that drive resistance to standard-of-care therapies targeting the cell division cycle in advanced breast cancer. The project will involve the analysis of molecules driving sensitivity and resistance to CDK4/6 inhibitors in breast cancer cells, the biochemical characterization of molecular pathways involved, and the validation of new therapies or therapeutic combinations to treat patients after progression to these inhibitors. The candidate will also be involved in the analysis of biopsies from these patients using machine learning algorithms in the search of biomarkers.
Requirements:
- Bachelor’s degree in biomedical or related degree.
- The candidates must be admitted or enrolled in a PhD Program in a Spanish University for the 2022-2023 academic year.
Additional information:
The candidate is expected to have experience in molecular and cellular biology techniques, cell cycle analysis and bioinformatic tools.
Application:
Potential candidates should submit a curriculum vitae and a letter of intent via email to selecciorrhh@vhio.net, including the reference “Ref. 14-2023” in the subject line of your email.
About VHIO:
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.
VHIO’s translation toward precision oncology: https://www.vhio.net
Vall d’Hebron Institute Oncology (VHIO) endorses the Requirements and Principles of the European Charter for Researchers, the Code of Conduct for the Recruitment of Researchers promoted by the European Commission and follows Equal Opportunities policies.
On 10th April 2018 VHIO was awarded the “HR Excellence in Research” logo. Our Institute was consequently granted permission to use the HR Excellence in Research Award logo as demonstration of its stimulating and favourable work environment in line with the Charter & Code.
